An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study Assessing Subjects Receiving Tipranavir 500 mg Stored at Controlled Temperature (Testproduct 30°C/70% RH) Compared With Tipranavir 500 mg Stored at Controlled Refrigerated Conditions (Reference Product 2-8°C), Orally Co-administered With Ritonavir 200 mg Under Fasting Conditions to Healthy Male and Female Volunteers

Trial Profile

An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study Assessing Subjects Receiving Tipranavir 500 mg Stored at Controlled Temperature (Testproduct 30°C/70% RH) Compared With Tipranavir 500 mg Stored at Controlled Refrigerated Conditions (Reference Product 2-8°C), Orally Co-administered With Ritonavir 200 mg Under Fasting Conditions to Healthy Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Tipranavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top